To compare two local anaesthetic drugs in Supraclavicular brachial plexus block in patients scheduled for upper limb surgeries

comparative study of Nalbuphine and Butorphanol as adjuvant to 0.75%Ropivacaine in Supraclavicular brachial plexus block in patients posted for upper limb surgeries-a double blinded randomized controlled trail - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/095551

Enrollment

120

Registered

2025-10-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: 1 ml of 10 mg Nalbuphine + 20 ml of 0.75 % Ropivacaine: 1 ml of 10 mg Nalbuphine + 20 ml of 0.75 % Ropivacaine is given for supraclavicular brachial plexus block in patients posted for

Eligibility

Inclusion criteria

Inclusion criteria: - ASA PS class 1 and 2 - Age 18 to 60 years - Weight more than 50 years

Exclusion criteria

Exclusion criteria: - Presence of coagulopathy, neuropathy, active infection at site, allergic to Local anesthetics. - BMI more than 35 kg per square meters - pregnancy, severe mental illness

Design outcomes

Primary

Measure	Time frame
To compare the duration of sensory blockade of Nalbuphine and Butorphanol as adjuvants to 0.75% Ropivacaine in supraclavicular brachial plexus block in patients undergoing upper limb surgeriesTimepoint: 18 months	—

Secondary

Measure	Time frame
-To compare the Hemodynamic parameters and adverse effects of both the adjuvants -To compare the time of first Rescue analgesia administered over 24 hours in both the groupsTimepoint: 10,20,30,40,50mins	—

Countries

India

Contacts

Public ContactDr Jebisha

Sri Manakula Vinayagar Medical College and Hospital

lazarus.suneeth@gmail.comn9894332543

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026